Davita Inc (DVA) Insider Charles Berg Sells 7,048 Shares of Stock
Davita Inc (NYSE:DVA) insider Charles Berg sold 7,048 shares of the company’s stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $69.24, for a total transaction of $488,003.52. Following the completion of the transaction, the insider now owns 5,359 shares in the company, valued at $371,057.16. The transaction was disclosed in a filing with the SEC, which is available at this link.
Shares of Davita Inc (NYSE:DVA) traded up $1.49 during mid-day trading on Friday, hitting $70.52. 3,010,400 shares of the stock traded hands, compared to its average volume of 1,674,372. The stock has a market cap of $13,492.22, a price-to-earnings ratio of 20.37, a P/E/G ratio of 14.38 and a beta of 0.97. Davita Inc has a 1-year low of $52.51 and a 1-year high of $71.47. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.35 and a current ratio of 1.40.
Davita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, November 7th. The company reported $0.81 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.94 by ($0.13). The company had revenue of $3.92 billion for the quarter, compared to analysts’ expectations of $3.91 billion. Davita had a return on equity of 13.31% and a net margin of 3.40%. The company’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.95 earnings per share. equities analysts expect that Davita Inc will post 3.42 earnings per share for the current year.
A number of research firms have issued reports on DVA. SunTrust Banks set a $57.00 target price on shares of Davita and gave the company a “hold” rating in a report on Sunday, October 15th. Royal Bank of Canada reduced their target price on shares of Davita from $64.00 to $60.00 and set a “sector perform” rating on the stock in a report on Wednesday, November 8th. KeyCorp restated a “hold” rating on shares of Davita in a report on Monday, November 13th. Wolfe Research upgraded shares of Davita from a “market perform” rating to an “outperform” rating in a report on Monday, October 23rd. Finally, J P Morgan Chase & Co lowered shares of Davita from a “neutral” rating to an “underweight” rating in a report on Monday, October 9th. Three analysts have rated the stock with a sell rating, five have assigned a hold rating, three have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $73.33.
Several hedge funds have recently made changes to their positions in DVA. Pzena Investment Management LLC lifted its holdings in shares of Davita by 2.1% during the 2nd quarter. Pzena Investment Management LLC now owns 3,398 shares of the company’s stock worth $220,000 after acquiring an additional 71 shares during the period. Airain ltd acquired a new stake in Davita during the 2nd quarter worth approximately $2,234,000. Jensen Investment Management Inc. increased its position in Davita by 24.2% during the 2nd quarter. Jensen Investment Management Inc. now owns 9,740 shares of the company’s stock worth $631,000 after purchasing an additional 1,900 shares in the last quarter. Schroder Investment Management Group increased its position in Davita by 53.9% during the 2nd quarter. Schroder Investment Management Group now owns 49,967 shares of the company’s stock worth $3,201,000 after purchasing an additional 17,497 shares in the last quarter. Finally, Riverhead Capital Management LLC increased its position in Davita by 10.6% during the 2nd quarter. Riverhead Capital Management LLC now owns 112,506 shares of the company’s stock worth $7,286,000 after purchasing an additional 10,775 shares in the last quarter. Institutional investors and hedge funds own 85.32% of the company’s stock.
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.